Qiagen N.V. (NYSE:QGEN) Q3 2023 Earnings Call Transcript

Page 5 of 5

Roland Sackers: Sure, Casey. I think I get you the details more or less during the call. But nevertheless, I would assume that suggest that we — in the remarks, we went down around about $400 million in terms of repayments end of September, which probably has an impact now on the net interest expense fourth quarter compared to the third quarter is probably around US$5 million. And for next year, probably again depends, of course, where interest rates are going all in I do think there is an impact around $0.02 to $0.03 EPS on the net level as well. So, I think that probably helps you. As I said, there’s a couple of repayments next year planned as well. And it’s clearly also again, $100 million in June next year and $500 million in November 24. And on the convert side, there might be another $ 500 million in December 25.

Operator: The last question comes from Andrew Brackmann of William Blair. Please go ahead.

Andrew Brackmann: Maybe just on the Sample tech business. You’ve obviously made a lot of investments there in automation over the last handful years. Can you just give us an update around what you’re seeing in those customers who have upgraded? And I guess, how should we be thinking about additional investments in automation for that business going forward?

Thierry Bernard: Thanks, Andrew. I think it was the right decision when we started, let’s say, five years ago to systematically upgrade our automation. As a reminder, QIAcube became QIAcube Connect. EZ1 became EZ1, and all the time, adding new features. As we said in today’s presentation, the next steps is QIAsymphony, where we are not only adding new connectivity features, but we are increasing the volume input, which is fundamental to better answer our already existing customers in liquid biopsy and taking more customers. This was a fundamental strategy to enhance our market shares and confirm our leadership. And we see customers for manual customers before sometimes being obviously moving to those automation platform, automated platform. The next steps, but it’s a bit too early to speak in details about it today, is to think about higher throughput automation, but we will come back to you in due term.

John Gilardi: Okay Thierry, operator, Roland, thank you very much for your time today on the call. If you have any follow-up questions, please do not hesitate to reach out to Phoebe, me. Thank you very much again for your interest in QIAGEN. Bye-bye.

Operator: Ladies and gentlemen, this concludes the conference call. Thank you for joining, and have a pleasant day. Goodbye.

Follow Qiagen Nv (NASDAQ:QGEN)

Page 5 of 5